323990.KQ Vaxcell-Bio Therapeutics Co. Ltd
- Market cap
- KRW 86.3B
- P/E
- -
- P/B
- 1.62x
- ROE
- -30.1%
- Dividend yield
- -
- Fundamental score
- 0.5/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 323990.KQ undervalued?
Graham numberThe Graham number of Vaxcell-Bio Therapeutics Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vaxcell-Bio Therapeutics Co. Ltd fundamental analysis
3 of 21 checks passedROE 0/2
Low return on equity (-30.1%), below 10%.
ROA 0/1
Return on assets (-27.3%) is below the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-24.1%) is below the industry median (4.8%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.4 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.6x) is below the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Vaxcell-Bio Therapeutics Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vaxcell-Bio Therapeutics Co. Ltd
Vaxcell-Bio Therapeutics Co., Ltd. develops and anticancer immunotherapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea.
Full company profileVaxcell-Bio Therapeutics Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vaxcell-Bio Therapeutics Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.7M | 1.90B | 7.06B | 6.32B |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.13M | 365M | 893M | 425M |
| Operating Income | -2.42B | -4.01B | -4.25B | -5.90B | -8.22B | -11.5B | -15.1B | -15.5B | -19.3B |
| EBITDA | - | - | - | - | -6.50B | -9.83B | -8.93B | -10.9B | -13.3B |
| Net Income | -6.45B | -1.25B | -3.98B | -4.76B | -6.83B | -10.3B | -10.6B | -13.3B | -16.0B |
| EPS | -909 | -73 | -265 | -236 | -448 | -447 | -464 | -576 | -692 |
| Balance Sheet | |||||||||
| Total Assets | 12.3B | 10.0B | 35.5B | 31.3B | 24.2B | 85.0B | 76.9B | 66.9B | 58.7B |
| Total Liabilities | 24.5B | 964M | 830M | 1.20B | 836M | 1.49B | 4.95B | 5.77B | 5.41B |
| Shareholders' Equity | -12.2B | 9.07B | 34.7B | 30.1B | 23.3B | 83.5B | 72.0B | 61.1B | 53.3B |
| Cash & Short-term Investments | 11.4B | 8.07B | 18.9B | 27.3B | 20.4B | 9.05B | 7.82B | 6.22B | 5.57B |
| Total Debt | 12.3B | 301M | 153M | - | - | - | - | - | - |
| Cash Flow | |||||||||
| Operating Cash Flow | -1.99B | -3.59B | -3.30B | -4.66B | -6.04B | -9.42B | -10.7B | -10.6B | -12.2B |
| Capital Expenditure | 467M | 903M | 26.9M | 2.23B | 290M | 199M | 4.07B | 6.78B | 3.23B |
| Free Cash Flow | - | - | -3.33B | -6.89B | -6.33B | -9.62B | -14.8B | -17.4B | -15.4B |
| Ratios | |||||||||
| ROE | - | -13.8% | -11.5% | -15.8% | -29.3% | -12.3% | -14.8% | -21.8% | -30.1% |
| ROA | -52.6% | -12.5% | -11.2% | -15.2% | -28.2% | -12.1% | -13.8% | -19.9% | -27.3% |
| Net Profit Margin | - | - | - | - | - | -74,865.8% | -559.4% | -189.1% | -253.6% |
| Debt to Equity | - | 0.03x | 0.00x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Vaxcell-Bio Therapeutics Co. Ltd dividends
Vaxcell-Bio Therapeutics Co. Ltd has not paid dividends in the last 8 fiscal years.
Last stock split: 1.2:1 on Nov 10, 2023.
Who owns Vaxcell-Bio Therapeutics Co. Ltd
- Insiders 12.34%
- Institutions 1.68%
- Public & others 85.98%
- Shares outstanding 23.2M
- Free float 18.2M
Vaxcell-Bio Therapeutics Co. Ltd company profile
- Company name
- Vaxcell-Bio Therapeutics Co. Ltd
- Ticker
- 323990.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 58
- Fiscal year end
- December
- Address
- 98-1 Sandan-gi, Hwasun-eup, South Korea
- Phone
- 82 6 1373 0046
- Website
- vaxcell-bio.com
About Vaxcell-Bio Therapeutics Co. Ltd
Vaxcell-Bio Therapeutics Co., Ltd. develops and anticancer immunotherapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea.